Global BiSpecific MAbS Market Research Report 2025

Publication ID:

PB504252476

Publication Date:

April 28, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for BiSpecific MAbS was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for BiSpecific MAbS is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for BiSpecific MAbS is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for BiSpecific MAbS in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of BiSpecific MAbS include Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Bristol Myers Squibb, Abbott, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for BiSpecific MAbS, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding BiSpecific MAbS.
The BiSpecific MAbS market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global BiSpecific MAbS market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the BiSpecific MAbS companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson & Johnson
Novartis AG
Hoffmann-La Roche Ltd.
Novo Nordisk A/S
Bayer AG
Thermo Fisher Scientific
Bristol Myers Squibb
Abbott
Segment by Type
Catumaxomab (Removab鈩�)
Blinatumomab
Emicizumab
Amivantamab
Others
Segment by Application
Hospital
Research Institute
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of BiSpecific MAbS company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global BiSpecific MAbS Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Catumaxomab (Removab鈩�)
1.2.3 Blinatumomab
1.2.4 Emicizumab
1.2.5 Amivantamab
1.2.6 Others
1.3 Market by Application
1.3.1 Global BiSpecific MAbS Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Research Institute
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global BiSpecific MAbS Market Perspective (2020-2031)
2.2 Global BiSpecific MAbS Growth Trends by Region
2.2.1 Global BiSpecific MAbS Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 BiSpecific MAbS Historic Market Size by Region (2020-2025)
2.2.3 BiSpecific MAbS Forecasted Market Size by Region (2026-2031)
2.3 BiSpecific MAbS Market Dynamics
2.3.1 BiSpecific MAbS Industry Trends
2.3.2 BiSpecific MAbS Market Drivers
2.3.3 BiSpecific MAbS Market Challenges
2.3.4 BiSpecific MAbS Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top BiSpecific MAbS Players by Revenue
3.1.1 Global Top BiSpecific MAbS Players by Revenue (2020-2025)
3.1.2 Global BiSpecific MAbS Revenue Market Share by Players (2020-2025)
3.2 Global BiSpecific MAbS Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by BiSpecific MAbS Revenue
3.4 Global BiSpecific MAbS Market Concentration Ratio
3.4.1 Global BiSpecific MAbS Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by BiSpecific MAbS Revenue in 2024
3.5 Global Key Players of BiSpecific MAbS Head office and Area Served
3.6 Global Key Players of BiSpecific MAbS, Product and Application
3.7 Global Key Players of BiSpecific MAbS, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 BiSpecific MAbS Breakdown Data by Type
4.1 Global BiSpecific MAbS Historic Market Size by Type (2020-2025)
4.2 Global BiSpecific MAbS Forecasted Market Size by Type (2026-2031)
5 BiSpecific MAbS Breakdown Data by Application
5.1 Global BiSpecific MAbS Historic Market Size by Application (2020-2025)
5.2 Global BiSpecific MAbS Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America BiSpecific MAbS Market Size (2020-2031)
6.2 North America BiSpecific MAbS Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America BiSpecific MAbS Market Size by Country (2020-2025)
6.4 North America BiSpecific MAbS Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe BiSpecific MAbS Market Size (2020-2031)
7.2 Europe BiSpecific MAbS Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe BiSpecific MAbS Market Size by Country (2020-2025)
7.4 Europe BiSpecific MAbS Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific BiSpecific MAbS Market Size (2020-2031)
8.2 Asia-Pacific BiSpecific MAbS Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific BiSpecific MAbS Market Size by Region (2020-2025)
8.4 Asia-Pacific BiSpecific MAbS Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America BiSpecific MAbS Market Size (2020-2031)
9.2 Latin America BiSpecific MAbS Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America BiSpecific MAbS Market Size by Country (2020-2025)
9.4 Latin America BiSpecific MAbS Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa BiSpecific MAbS Market Size (2020-2031)
10.2 Middle East & Africa BiSpecific MAbS Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa BiSpecific MAbS Market Size by Country (2020-2025)
10.4 Middle East & Africa BiSpecific MAbS Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Details
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson BiSpecific MAbS Introduction
11.1.4 Johnson & Johnson Revenue in BiSpecific MAbS Business (2020-2025)
11.1.5 Johnson & Johnson Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG BiSpecific MAbS Introduction
11.2.4 Novartis AG Revenue in BiSpecific MAbS Business (2020-2025)
11.2.5 Novartis AG Recent Development
11.3 Hoffmann-La Roche Ltd.
11.3.1 Hoffmann-La Roche Ltd. Company Details
11.3.2 Hoffmann-La Roche Ltd. Business Overview
11.3.3 Hoffmann-La Roche Ltd. BiSpecific MAbS Introduction
11.3.4 Hoffmann-La Roche Ltd. Revenue in BiSpecific MAbS Business (2020-2025)
11.3.5 Hoffmann-La Roche Ltd. Recent Development
11.4 Novo Nordisk A/S
11.4.1 Novo Nordisk A/S Company Details
11.4.2 Novo Nordisk A/S Business Overview
11.4.3 Novo Nordisk A/S BiSpecific MAbS Introduction
11.4.4 Novo Nordisk A/S Revenue in BiSpecific MAbS Business (2020-2025)
11.4.5 Novo Nordisk A/S Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Details
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG BiSpecific MAbS Introduction
11.5.4 Bayer AG Revenue in BiSpecific MAbS Business (2020-2025)
11.5.5 Bayer AG Recent Development
11.6 Thermo Fisher Scientific
11.6.1 Thermo Fisher Scientific Company Details
11.6.2 Thermo Fisher Scientific Business Overview
11.6.3 Thermo Fisher Scientific BiSpecific MAbS Introduction
11.6.4 Thermo Fisher Scientific Revenue in BiSpecific MAbS Business (2020-2025)
11.6.5 Thermo Fisher Scientific Recent Development
11.7 Bristol Myers Squibb
11.7.1 Bristol Myers Squibb Company Details
11.7.2 Bristol Myers Squibb Business Overview
11.7.3 Bristol Myers Squibb BiSpecific MAbS Introduction
11.7.4 Bristol Myers Squibb Revenue in BiSpecific MAbS Business (2020-2025)
11.7.5 Bristol Myers Squibb Recent Development
11.8 Abbott
11.8.1 Abbott Company Details
11.8.2 Abbott Business Overview
11.8.3 Abbott BiSpecific MAbS Introduction
11.8.4 Abbott Revenue in BiSpecific MAbS Business (2020-2025)
11.8.5 Abbott Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Johnson & Johnson
Novartis AG
Hoffmann-La Roche Ltd.
Novo Nordisk A/S
Bayer AG
Thermo Fisher Scientific
Bristol Myers Squibb
Abbott

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂